Nasdaq
$41.53▼ 0.19%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $99.69BShares out 2400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.1Regular26.10.02 01:096-KKey event#●●●#●●●
SanofiBullish
Sanofi and Regeneron have expanded their long-standing collaboration to develop next-generation, long-acting immunology antibodies. Under the agreement, Sanofi will pay Regeneron $1 billion upfront, with potential for up to an additional $7 billion in future development and commercialization milestone payments.…more
$41.53-0.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17Pre-market26.09.17 19:096-KKey event
Sanofi
Sanofi has entered into a strategic partnership with Cheplapharm to divest a portfolio of 20 mature medicines and three manufacturing sites. In exchange, Sanofi will receive a 26.4% equity stake in Cheplapharm, with the transaction expected to have no impact on Sanofi's 2026 financial guidance. The commercial transfer is planned to begin in the first quarter of 2027 and is expected to be fully completed by the third quarter of 2027.…more
$41.53-0.19%vs prev closeView filingShare - 8.25Pre-market26.08.25 19:06N-PXOther
Sanofi
Sanofi filed its N-PX report with the SEC on August 25, 2026. This document serves as the annual report detailing the proxy voting records for securities held by management investment companies.…more
$41.53-0.19%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:02#●●●#●●●#●●●
Teva and Sanofi Report Positive Phase 2b Data for Duvakitug
Teva and Sanofi announced that their investigational drug duvakitug maintained clinical efficacy in patients with ulcerative colitis and Crohn's disease through 44 weeks of a phase 2b study. The data demonstrated consistent improvements in clinical remission and endoscopic response, supporting the drug's potential as a treatment for inflammatory bowel disease.…more
$41.53-0.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.16Overnight26.10.16 14:19
●●●●●●●● ●●●●● ●●●●●●
Recursion Pharmaceuticals has raised $200 million through a stock offering priced at $3.25 per share. Additionally, the company secured a $10 million milestone payment after Sanofi selected a candidate from their collaborative research program.…more
$41.53-0.19%vs prev closeShareBenzinga - 10.15Regular26.10.16 02:43
●●●●●●●● ●●●●● ●●●●●●
Sanofi has entered into legally binding commitments with the European Commission to resolve antitrust concerns regarding misleading claims about a rival flu vaccine. The company will implement corrective measures and refrain from disparaging the competitor's product until 2030.…more
$41.53-0.19%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report